Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report

Yue Zhang,1 Rushan Xia1,2 1Department of Dermatology, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, People’s Republic of China; 2Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of ChinaCorrespondence: Rushan Xia, Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of China, Tel +8618861843704, Email [email protected]: This article reports a 59-year-old female patient who was diagnosed with segmental hyaline vasculitis and treated with tofacitinib for 2 months. In this case, multiple dark purplish-red spots were seen on both lower limbs, which did not fade with pressure. Flaky dark red spots, petechiae, ulcers, and necrosis were seen on the ankles. Histopathological manifestations were consistent with segmental hyaline vasculitis. The lesions subsided after the patient was treated with oral tofacitinib 5 mg twice daily for 1 month.Keywords: cutaneous vasculitis, segmental hyaline vasculitis, tofacitinib